The Outcome of HIV-Positive Late Presenters According to Detectable CMV DNA and Anti-CMV Treatment. Issue 5 (July 2018)

• Record Type: Journal Article
• Authors: Bigliano, Paolo; Calcagno, Andrea; Lucchini, Anna; Audagnotto, Sabrina; Montrucchio, Chiara; Marinaro, Letizia; Alcantarini, Chiara; Ghisetti, Valeria; Perri, Giovanni Di; Bonora, Stefano
• Is Part Of: Antiviral therapy. Volume 23:Issue 5(2018)
• Page Start: 451
• Page End: 456
• Publication Date: 2018-07
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP3221
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: HIV late presenters are at high risk of cytomegalovirus (CMV) reactivation and end-organ disease. CMV viraemia has been associated with poor survival but the effect of anti-CMV treatment has not been studied in this setting. Methods: HIV-positive patients were included in a retrospective study if presenting with <350 CD4 + T-cells/μl and starting an antiretroviral treatment within 3 months of the diagnosis. Primary end point was 5-year survival according to the presence of CMV viraemia, CMV end-organ disease and anti-CMV treatment. Results: 302 patients were included. 157 patients (52%) presented CMV viraemia (CMV-V) and 44 (14.6%) CMV end-organ disease (CMV-EOD). 5-year mortality was higher in CMV-EOD and CMV-V patients than in CMV-negative patients (11.4 versus 9.6 versus 0%; P =0.002). In patients with CMV-V, 5-year mortality was numerically higher in untreated patients (12.9% versus 6.9%; P =0.257) without reaching statistical significance. At univariate analysis the diagnosis of serious opportunistic infections (cryptococcosis, progressive multifocal leukoencephalopathy, lymphoma; P =0.001) and the absence of a negative CMV DNA in the follow-up ( P <0.001) were associated with poor outcome. At multivariate analysis HCV coinfection ( P =0.016; aOR 6.98, 95% CI 1.50, 32.59), the absence of a negative CMV DNA in the follow-up ( P <0.001; aOR 19.40, 95% CI 3.70, 101.64) and marginally the absence of anti-CMV treatment ( P =0.052; aOR 4.944, 95% CI 0.99, 24.73) were independent predictors of poor outcome. Conclusions: CMV reactivation in HIV-positive patients with poor immunity is associated with worse prognosis: the pre-emptive use of anti-CMV therapy was associated with a better outcome in patients with CMV-V.